Mobilum Techs (OTC:MBLMF) Stock, Quote.Headers.trade-ideas

Mobilum Technologies Inc is a fintech company that builds powerful yet simple integrations for small and large businesses to accept payments and manage their cryptocurrency businesses online.

MOBILUM TECHNOLOGIES INC by MOBILUM TECHNOLOGIES INC.

Mobilum Technologies Inc

On Monday, Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) presented at the JP Morgan <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42943900/incyte-highlights-commercial-growth-clinical-progress-and-2025-milestones-at-the-43rd-annual-j-p-m" rel="noreferrer noopener">Healthcare Conference</a>.
Incyte outlined a pivotal year ahead during its JPM presentation, describing 2025 as a &#8220;year of defining catalysts.&#8221;
The company anticipates four potential drug launches, pivotal trial readouts, and advancements in its pipeline.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42069374/incytes-750-million-escient-deal-faces-setback-with-toxicology-issues-in-two-investigational-drugs-analyst-flags-challenges" rel="noreferrer noopener">Incyte&#8217;s $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges</a>
Incyte estimates the anticipated four launches could contribute approximately $1 billion in incremental revenues by 2029.
The company is also <a target="_blank" href="https://investor.incyte.com/static-files/f0037aa1-59bf-467c-a2cd-59fff2c6393c" rel="noreferrer noopener">preparing</a> for a transformative year, with highlights including four pivotal trial results, seven proof-of-concept data readouts, and at least three Phase 3 study initiations.
Planned 2025 Drug Launches
<ul>
<li>Among the near-term launches are Niktimvo, approved for third-line chronic graft-versus-host disease, expected to hit the U.S. market in the first quarter of 2025.</li>
<li>Additional launches include ruxolitinib cream for pediatric atopic dermatitis, tafasitamab for follicular lymphoma, and retifanlimab for squamous cell anal carcinoma, all pending approvals in the second half of the year.</li>
</ul>
Strategic Growth Toward 2030
<ul>
<li>Incyte&#8217;s long-term vision includes more than ten impactful product launches by 2030.</li>
<li>Key candidates include povorcitinib, which is being developed for multiple indications and has significant market opportunities.</li>
<li>For moderate-to-severe hidradenitis suppurativa alone, Phase 3 data is expected in the first half of 2025, targeting a $3 billion U.S. market with over 300,000 affected patients.</li>
<li>The drug is also being studied for extensive nonsegmental vitiligo and prurigo nodularis, which are underserved conditions with high market potential. Phase 3 data for these indications are expected in 2026, and combined market opportunities will exceed $4 billion.</li>
</ul>
Additional Promising Assets
<ul>
<li>Incyte highlighted the potential of its mCALR program for myelofibrosis and Essential thrombocythemia with CALR mutation. Proof-of-concept data are anticipated in 2025</li>
<li>A CDK2 inhibitor aims to address unmet needs in ovarian cancer. It is expected to enter a pivotal trial in 2025.</li>
</ul>
Incyte&nbsp;reported&nbsp;third-quarter revenue&nbsp;of $1.14 billion, up 24% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41637452/incytes-jakafi-demand-is-strong-analyst-upgrades-stock" rel="noreferrer noopener">consensus of $1.08 billion</a>.
Jakafi&nbsp;(ruxolitinib) net product revenues increased to&nbsp;$741.18 million, up 16% year over year, primarily due to a 10% increase in total demand.
Price Action: INCY stock closed at $72.37 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42958251/on-semi-sees-utilization-cuts-as-ev-demand-softens-analyst-warns" target="_blank" rel="noreferrer noopener">ON Semi Sees Utilization Cuts As EV Demand Softens, Analyst Warns</a></li>
</ul>

Biotech

Large Cap

News

Health Care

General

INCY

Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline

Wells Fargo analyst Michael Brown maintains Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Overweight and lowers the price target from $197 to $191.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Apollo Global Management, Lowers Price Target to $191

BKNG TRADES UP 1.7% AFTER ALERT
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="682" height="605" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13211135/Screen-Shot-2025-01-13-at-4.14.36-PM.png" alt="" class="wp-image-4629" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13211135/Screen-Shot-2025-01-13-at-4.14.36-PM.png 682w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/13211135/Screen-Shot-2025-01-13-at-4.14.36-PM-300x266.png 300w" sizes="(max-width: 682px) 100vw, 682px" /></figure>
BOOKING HOLDINGS, Inc. (BKNG) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
At 10:03 AM on January 13th, a significant trading signal occurred for Booking Holdings, Inc. (BKNG) as it demonstrated a Power Inflow at a price of $4700.54. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Bookings&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Booking&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for BKNG, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $4700.54. The returns on the High price ($4780.57) and Close price ($4763.76) after the Power Inflow were respectively 1.7% and 1.3%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case, the high of the day and close were very close but that is not always the case
Past Performance is Not Indicative of Future Results

Trading Ideas

Tradepulse Power Inflow Alert: Booking Holdings Inc. (BKNG) Moves Over 80 Points After Alert

WIIM

Castellum shares are trading higher after the company announced it secured a $3.2 million contract to enhance cyber-supply chain risk management for naval aircraft systems.

Goldman Sachs analyst Susan Maklari maintains Fortune Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBIN#NYSE">FBIN</a>) with a Buy and lowers the price target from $97 to $85.

FBIN

Goldman Sachs Maintains Buy on Fortune Brands, Lowers Price Target to $85

Asset Sales

Reading International Entered Agreement To Sell Its Wellington, New Zealand Properties To Prime Property Group For NZ$38M

Utilities, the S&amp;P 500&#8217;s biggest laggard in 2023, staged a remarkable rebound in 2024, fueled by surging electricity demand driven by artificial intelligence, electrification, <a href="https://www.benzinga.com/topic/utilities">and decarbonization trends.</a>
Among the beneficiaries of this momentum are ETFs with exposure to utility stocks like GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>), Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) and NextEra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>), which may reap the benefits of the growing energy needs of data centers.
Three ETFs that can cash in on this trend include the Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>), Vanguard Utilities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VPU#NYSE">VPU</a>), and Fidelity MSCI Utilities Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUTY#NYSE">FUTY</a>), each offering a way to invest in a bunch of companies supporting the energy-intensive operations of data centers.
See Also: <a href="https://www.benzinga.com/25/01/42961753/analyst-sees-broadening-rally-in-semis-coming-in-2025-2-top-stock-picks-and-2-to-avoid">Analyst Sees ‘Broadening Rally' In Semiconductors In 2025: 2 Top Stock Picks, 2 To Avoid</a>
The Utilities Select Sector SPDR Fund, with an expense ratio of a mere 0.09% and assets of $16.39 billion under management, holds promise. NextEra,&nbsp;Constellation Energy&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>), and Vistra are among the top holdings of this fund, which mirrors the Utilities Select Sector Index as a benchmark.
The Vanguard Utilities ETF has an expense ratio of 0.10% and $8.8 billion in assets under management. This fund also gives significant weightage to NextEta, Constellation, and Vistra.
The Fidelity MSCI Utilities Index ETF is exposed to Nextra, Constellation and Vistra as well, and carries an expense ratio of 0.08%. 
Why Utilities Are Thriving
We often hear the phrase &#8220;data is the new oil&#8221; these days, and data centers, the backbone of the digital world, are often overlooked as power consumers. Supporting real-time communication, data storage, and cloud-based operations to run technologies like smartphones and connected appliances requires massive electricity, and there is one sector that data centers rely on for power &#8211; utility providers.
According to the International Energy Agency, data centers and data transmission networks comprise 1%-1.5% of global electricity use.
The increasing integration of AI, which relies on energy-intensive computations, further boosts this demand. Power demand growth for utilities—historically stagnant at 1%-2% annually—is now expected to climb to about 6-8% annually for the next decade, driven by these technological trends, <a href="https://www.fidelity.com/learning-center/trading-investing/outlook-utilities">reported </a>Fidelity Investments.
Utilities are traditionally a defensive sector with stability and lower sensitivity to economic fluctuations, as evident from &#8220;a lower beta relative to other sectors to the broad market,&#8221; per Fidelity.
These factors appealed to investors during a dynamic year. According to a Deloitte&nbsp;<a href="https://www2.deloitte.com/us/en/insights/industry/technology/technology-media-and-telecom-predictions/2025/genai-power-consumption-creates-need-for-more-sustainable-data-centers.html" target="_blank" rel="noopener">report</a>, the annual power consumption of AI data centers&nbsp;is anticipated to increase 10 times from 2022 and hit 90 terawatt-hours by 2026. The utility sector and ETFs exposed to it appear to be on an upward trajectory.
See Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/01/42958533/how-trumps-maganomics-could-power-industrials-focused-etfs">How Trump's ‘Maganomics' Could Power Industrials-Focused ETFs</a></li>
</ul>
Photo: Sundry Photography/ Shutterstock.com

Sector ETFs

ETFs

FUTY

Utilities Rebound As AI Powers Energy Demand: 3 ETFs To Watch

Goldman Sachs analyst Susan Maklari maintains D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) with a Buy and lowers the price target from $200 to $171.

Goldman Sachs Maintains Buy on D.R. Horton, Lowers Price Target to $171

RILY

B. Riley Financial shares are trading higher after the company filed Q2 financial results and provided updates on its total cash balance.

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ESALY#OTC">ESALY</a>) and Biogen Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) Biologics License Application (BLA) for lecanemab-irmb (Leqembi) subcutaneous autoinjector (SC-AI) for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42964327/fda-accepts-leqembi-lecanemab-irmb-biologics-license-application-for-subcutaneous-maintenance-dosi" rel="noreferrer noopener">weekly maintenance dosing</a>.
Leqembi is indicated for Alzheimer&#8217;s disease in patients with Mild Cognitive Impairment or mild dementia stage of the disease.
A Prescription Drug User Fee Act (PDUFA) action date is August 31, 2025.
The BLA is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modeling of observed data.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42397286/biogen-downgraded-on-pipeline-setbacks-and-leqembi-sales-slowdown" rel="noreferrer noopener">Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown</a>
If the FDA approves Leqembi subcutaneous maintenance dosing, Leqembi will be the only treatment for AD that can be administered subcutaneously at home using an autoinjector.
The injection process is expected to take, on average, 15 seconds. As part of the SC-AI 360 mg weekly maintenance regimen, patients who have completed the biweekly intravenous (IV) initiation phase, the exact period under discussion with the FDA, would receive weekly doses expected to maintain the clinical and biomarker benefits.
Long-term three-year Leqembi data presented at the Alzheimer&#8217;s Association International Conference (AAIC) 2024 suggest that early and continuing treatment may prolong the benefit of therapy even after plaque is cleared from the brain.
Eisai serves as the lead for lecanemab&#8217;s development and regulatory submissions globally. Eisai and Biogen co-commercialize and co-promote the product, and Eisai has the final decision-making authority.
On Monday, Biogen submitted an unsolicited bid to acquire all of the outstanding shares of&nbsp;Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), which Biogen does not already own,<a target="_blank" href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say" rel="noreferrer noopener"> for&nbsp;$7.22&nbsp;per share</a>.
Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the Zurzuvae launch for postpartum depression (PPD).
Price Action: BIIB stock closed at $150.18&nbsp;on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42960291/metas-content-moderation-changes-alarm-advertisers-as-zuckerberg-aligns-with-trump-and-musk" target="_blank" rel="noreferrer noopener">Meta&#8217;s Content Moderation Changes Alarm Advertisers as Zuckerberg Aligns with Trump and Musk</a></li>
</ul>

BIIB

ESALY

FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi

JMP Securities analyst Trevor Walsh reiterates CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Market Outperform and maintains $360 price target.

Reiteration

CYBR

JMP Securities Reiterates Market Outperform on CyberArk Software, Maintains $360 Price Target

Wells Fargo analyst Roger Read maintains ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) with a Overweight and lowers the price target from $134 to $132.

Wells Fargo Maintains Overweight on ConocoPhillips, Lowers Price Target to $132

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Loop Capital analyst Gary Mobley initiated coverage on Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy rating and announced a price target of $175. AMD shares closed at $117.32 on Monday. <a href="https://www.benzinga.com/quote/AMD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities analyst Michael Ciarmoli initiated coverage on Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) with a Buy rating and announced a price target of $579. Lockheed Martin shares closed at $483.16 on Monday. <a href="https://www.benzinga.com/quote/LMT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst Omotayo Okusanya initiated coverage on Rexford Industrial Realty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REXR#NYSE">REXR</a>) with a Hold rating and announced a price target of $40. Rexford Industrial Realty shares closed at $38.27 on Monday. <a href="https://www.benzinga.com/quote/REXR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>CICC analyst Zijie Yang initiated coverage on Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with an Outperform rating. Roblox shares closed at $61.37 on Monday. <a href="https://www.benzinga.com/quote/RBLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Mikhail Goberman initiated coverage on Mr. Cooper Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) with a Market Outperform rating and announced a price target of $115. Mr. Cooper shares closed at $92.25 on Monday. <a href="https://www.benzinga.com/quote/COOP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AMD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="606" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/14090155/image-88-1024x606.png" alt="" class="wp-image-732494" style="width:559px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/14090155/image-88-1024x606.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/14090155/image-88-300x178.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/14090155/image-88-768x455.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/14090155/image-88.png 1093w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/42965686/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-january">Top 2 Industrials Stocks That May Fall Off A Cliff In January</a></li>
</ul>

Initiation

Markets

COOP

RBLX

REXR

This AMD Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

FERG

WINT Water Intelligence And Ferguson Collaborate; WINT's Solutions Available In Ferguson's Distribution Network

Guidance

Eli Lilly Expects 2024 Revenue of $45.0B, About 3% Below Guidance Range Issued On Oct. 30; Issues 2025 Guidance of $58.0B-$61.0B

PRTG

Portage Biotech shares are trading higher after the company announced the spinoff of its subsidiary Cyncado Therapeutics.

ITT Cannon Connectors Qualified For Deployment On Nett Warrior Soldier-Worn Mission Command System By U.S. Army Program Executive Office For Ground Soldier Systems

Wells Fargo analyst Andrew Bauch initiates coverage on Jack Henry &amp; Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>) with a Underweight rating and announces Price Target of $155.

JKHY

Wells Fargo Initiates Coverage On Jack Henry & Associates with Underweight Rating, Announces Price Target of $155

VRME

VerifyMe shares are trading higher after the company announced it entered a warrant inducement transaction for $4.7 million in proceeds.

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Terreno Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $66.5, a high estimate of $72.00, and a low estimate of $60.00. Observing a downward trend, the current average is 5.27% lower than the prior average price target of $70.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1736863254_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Terreno Realty. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Mitch Germain</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Mitch Germain</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$68.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Greg McGinniss</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$67.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Terreno Realty. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Terreno Realty compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Terreno Realty's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Terreno Realty's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TRNO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Terreno Realty analyst ratings.</a>
<h2>About Terreno Realty</h2>
Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.
<h3>Terreno Realty: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Terreno Realty displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 20.16%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Terreno Realty's net margin is impressive, surpassing industry averages. With a net margin of 36.62%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Terreno Realty's ROE stands out, surpassing industry averages. With an impressive ROE of 1.03%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Terreno Realty's ROA excels beyond industry benchmarks, reaching 0.81%. This signifies efficient management of assets and strong financial health.
Debt Management: Terreno Realty's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.19.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Mobilum Techs

Mobilum Techs (MBLMF) Forecast

Mobilum Techs (OTC:MBLMF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga